Ge Long Hui A P P·2025-10-17 10:46Core Points - Fosun Pharma (600196.SH) announced that the Shenzhen Biopharmaceutical Industry Fund intends to participate in the A-round financing of its subsidiary, Fosun Kairui, with a total investment of 600 million yuan to subscribe for no more than 524.44 million yuan of new registered capital [1] - To motivate the core team of Fosun Kairui, 14 co-investors, including current directors and core management, plan to invest a total of 3.525 million yuan to subscribe for 3.081 million yuan of new registered capital [1] - A stock incentive plan was approved by the board of directors and shareholders' meeting of Fosun Kairui, allowing the issuance of incentive rights corresponding to no more than 93.22 million yuan of registered capital at a price of 0.76 yuan per 1 yuan of registered capital [1] Shareholding Structure - After the completion of the capital increase, co-investment, and stock incentive plan, the group's shareholding in Fosun Kairui will decrease from approximately 97.78% to a maximum of 77.10%, while Fosun Kairui will remain a controlled subsidiary of the company [2]